Log in or Sign up for Free to view tailored content for your specialty!
Therapeutics/Diagnostics News
Linaclotide improves rate of bowel movements, consistency in children with constipation
Treatment with once-daily linaclotide was well-tolerated and resulted in significant improvement in spontaneous bowel movements and stool consistency vs. placebo among children with functional constipation, researchers reported.
Infliximab levels above 6.9 mg/L at week 14 predict sustained remission in pediatric IBD
Infliximab concentrations above 6.9 mg/L at 14 weeks after initiation of treatment predicted sustained remission between 26 and 52 weeks in children with inflammatory bowel disease, according to researchers in the Netherlands.
Log in or Sign up for Free to view tailored content for your specialty!
Prebiotic inulin causes ‘beneficial changes’ in microbiome of children with IBD
LAS VEGAS — Supplementation with prebiotic oligofructose-enriched inulin resulted in short-term microbiome changes as early as 4 weeks among children with inflammatory bowel disease, according to a presenter at Crohn’s & Colitis Congress.
Anti-TNF therapy significantly improves growth disturbances in pediatric Crohn’s
LAS VEGAS — Although a substantial proportion of children with Crohn’s disease had growth disturbances at initiation of anti-tumor necrosis factor therapy, “significant improvement” was noted up to 24 months after treatment, data showed.
Dietitians have ‘very diverse, rich roles,’ add value to the IBD care team
LAS VEGAS — Partnering with a dietitian who specializes in inflammatory bowel disease can augment patient care through nutritional assessment, dietary counseling and perioperative optimization, according to a presenter.
Growing armamentarium of therapies for IBD has ‘truly revolutionized’ care
LAS VEGAS —A presenter at the Crohn’s & Colitis Congress outlined some of the newer therapies that have expanded the current “arsenal of tools” for the treatment of inflammatory bowel disease.
Q&A: Zymfentra ‘gives patients an option’ for at-home maintenance therapy of IBD
The FDA’s approval of Zymfentra in fall 2023 offers patients the “flexibility” of a subcutaneous therapy option for moderately to severely active ulcerative colitis and Crohn’s disease, Stephen B. Hanauer, MD, told Healio in an interview.
VIDEO: ‘Dispel the myth of personal responsibility’ to combat obesity stigma
In the latest installment of Healio’s diversity, equity and inclusion video series with the ASGE, Catherine T. Hudson, MD, addressed how to combat emerging stigma around new anti-obesity medications such as glucagon-like peptide agonists.
Glucose-lowering therapies linked to reduced risk for CV events in type 2 diabetes, MASLD
Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists were associated with lower risk for cardiovascular events in type 2 diabetes, with or without metabolic dysfunction-associated steatotic liver disease.
Novel blood-sensing capsule ‘highly accurate’ in detecting upper GI bleeding
The PillSense System, a novel blood-sensing swallowed capsule device, safely detected blood in patients with clinically suspected upper gastrointestinal bleeding with a sensitivity of 92.9% and a specificity of 90.6%, data showed.
-
Headline News
CDC: 1 dead in multistate outbreak of E. coli linked to organic carrots
November 18, 20241 min read -
Headline News
Obesity drugs could help lower alcohol intake
November 18, 20243 min read -
Headline News
Pediatric asthma ‘potential source of cognitive difficulty’
November 18, 20242 min read
-
Headline News
CDC: 1 dead in multistate outbreak of E. coli linked to organic carrots
November 18, 20241 min read -
Headline News
Obesity drugs could help lower alcohol intake
November 18, 20243 min read -
Headline News
Pediatric asthma ‘potential source of cognitive difficulty’
November 18, 20242 min read